Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression (the "ACLR8-LR" Study)

NCT05947812 is registered in ClinicalTrials.gov with 60P Australia Pty Ltd as lead sponsor.

NCT NCT05947812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05947812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression (the "ACLR8-LR" Study)
Lead sponsor
60P Australia Pty Ltd
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2023
Completion date
April 27, 2024
Enrollment
148 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19 disease, infectious disease, mild to moderate covid 19 disease, sars-cov-2, severe acute respiratory syndrome coronavirus 2